National Coal Corp. to Release Third Quarter Financial Results and Host Conference Call
|
|
|
| Posted
:
Wed, 04 Nov 2009 20:13:07 GMT |
| Author
:
National Coal Corp.
|
| Category
:
Press Release |
| News Alerts by
Email ( click
here ) |
| Press Release
News |
Home
|
|
|
|
KNOXVILLE, Tenn. - (Business Wire) National Coal Corp. (Nasdaq: NCOC), a Central and Southern Appalachian coal producer, will release its third quarter financial results on Thursday, November 5, 2009, via Business Wire. A copy of the press release will be available to the public via the media and the Company’s website at www.nationalcoal.com. Management will host a conference call at 4:30 p.m. Eastern Time, Thursday, November 5, 2009, to discuss the Company’s third quarter 2009 financial results. The conference call will include a question and answer period. | | | Call Details | | | | Thursday, November 5, 2009 | | | | 4:30 p.m. ET | | | | U.S. participants dial 1-800-920-7487 code 25374717# | | | | International participants dial 1-404-920-1710 code 25374717# | | | The call is open to the public, and following the call anyone can access audio playback information and a text transcript via the Company’s website at www.nationalcoal.com/investors.php. Questions about the call should be directed to National Coal’s Press and Investor Relations contact, Christine Pietryla, via email at cpietryla@nationalcoal.com. About National Coal Corp. Headquartered in Knoxville, Tenn., National Coal Corp., through its wholly-owned subsidiary, National Coal Corporation, is engaged in coal mining in East Tennessee. Currently, National Coal employs about 340 people. National Coal sells steam coal to electric utilities and industrial companies in the Southeastern United States. For more information and to sign-up for instant news alerts visit www.nationalcoal.com.
for National Coal Corp.
Christine Pietryla, 865-690-6900, ext. 150
(Investor Relations)
|
Copyright © 2008
Business Wire. All rights reserved.
|
|
|
|
|
Related
News
Noah Education Files Form 20-F for Fiscal Year 2009
SHENZHEN, China, Nov. 23 /PRNewswire-Asia-FirstCall/ -- Noah Education
Holdings Ltd. (NYSE: NED) ("Noah" or "the Company"), a leading provider of
interactive educational content and education services in China, tod...
Controversial Award-Winning Film Obsession Available for Free Online Streaming
NEW YORK, Nov. 23 /PRNewswire/ -- The producers of Obsession Radical Islam's War Against the West are making the full-length feature documentary available for online viewing free of charge over Thanksgiving weekend.
The film, whose retail price is $19.95, ...
Victory Pharma, Inc. Announces Launch of NAPRELAN(R) Dose Card
SAN DIEGO, Nov. 23 /PRNewswire/ -- Victory Pharma, Inc. ("Victory") announced today the launch of NAPRELAN® Dose Card, a further extension of Victory's NAPRELAN franchise.
NAPRELAN Dose Card is designed for patients who require relief from mild to moderate pai...
Fragmentation Prevention and Energy Savings
BURBANK, CA -- 11/23/09 --
For many years, conservation of energy has been
a serious issue. It traces back to our natural resources such as coal and
water and the amount of carbon being released in to the atmosphere, but it
also has a more practica..
Mediasite by Sonic Foundry Named Best Webcasting/Presentations Solution by Streaming Media Readers
MADISON, Wis., Nov. 23 /PRNewswire/ -- Mediasite by Sonic Foundry, Inc. (Nasdaq: SOFOD), the recognized market leader for rich media webcasting and knowledge management, has been voted Best Webcasting/Presentations Solution in the ...
RXi Pharmaceuticals Wins 2009 RNAi Technology Innovation of the Year Award from Frost & Sullivan
WORCESTER, Mass. -
RXi Pharmaceuticals Corporation (Nasdaq: RXII), a biopharmaceutical
company pursuing the development and commercialization of proprietary
therapeutics based on RNA interference (RNAi), today reported that the
Company has received Frost & Sullivan’s 2009 North Ame
SciClone Announces Enrollment Completion in Phase 2 Oral Mucositis Trial of SCV-07
FOSTER CITY, CA -- 11/23/09 --
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that patient enrollment is complete ahead of schedule
for its phase 2 trial of SCV-07 -- a small molecule synthetic peptide with
immunomodulating propertie..
|
|
|
|
|
|
|
|
|
